在体外溶栓模型中跟踪剪切流下钱德勒环形成的全血凝块的纤维蛋白溶解
2024年4月19日
体外 溶栓测定通常难以复制 体内 条件，无论是在正在消化的模型血栓中还是在发生溶栓的环境中。在此，我们探讨了如何将钱德勒环和实时荧光流动纤维蛋白溶解测定 （RT-FluFF） 偶联用于高保真、 离体、凝块溶解监测。
血栓形成与许多疾病有关，目前的治疗有严重出血的风险。循环系统流量显着影响血凝块结构。将流动纳入体外模型可以提高其生理相关性，从而增强对体内测试更好候选者的选择。
用于研究纤维蛋白溶解剂的测定主要利用静态凝块或微流体系统来评估裂解时间、凝块结构或粘弹性等特性。静态凝块溶解测定通常依靠分光光度法测量或凝块质量测定作为评估纤维蛋白溶解效率的终点。目前的溶栓测试使用静态形成的凝块，其结构与在流动条件下形成的凝块不同。
微流体系统考虑了流动动力学，但其较小的尺度会产生独特的血流动力学和凝块结构。目前开发的 RT-FluFF 检测便于在生理流动条件下实时监测纤维蛋白溶解。这意味着我们现在有一个平台，可以控制多个参数，以模拟更接近体内研究模型的条件，以便在筛选新的溶栓剂时更好地翻译。
概览
本研究调查了体外溶栓测定在复制体内条件中的局限性。通过将Chandler环与实时荧光流动纤维蛋白溶解测定法（RT-FluFF）结合起来，研究旨在提高离体血凝块溶解监测的准确性。
关键研究组成部分
科学领域
- 血栓形成
- 溶栓
- 纤维蛋白溶解
背景
- 血栓形成与多种医疗状况相关。
- 目前的血栓治疗方法存在严重出血的风险。
- 血流显著影响凝块结构。
- 静态测定可能无法准确反映体内条件。
研究目的
- 提高体外溶栓测定的生理相关性。
- 提高体内测试候选者的选择性。
- 评估流动对凝块溶解效率的影响。
所用方法
- Chandler环用于模拟血流。
- 实时荧光流动纤维蛋白溶解测定法（RT-FluFF）。
- 在受控环境中监测凝块溶解。
- 比较静态和流动条件。
主要结果
- 流动条件显著影响凝块结构和溶解。
- RT-FluFF提供了高保真的凝块溶解监测。
- 结合方法增强了测定结果的相关性。
- 改进的测定可能导致更好的治疗候选者。
结论
- 在溶栓测定中加入流动可以提高准确性。
- 离体监测可以更好地模拟体内条件。
- 未来的研究应该集中在完善这些方法上。
常见问题
Executive Industry Relevance
Physiologically relevant in-vitro thrombolysis models are critical for improving predictive confidence in thrombolytic drug discovery and reducing translational failure rates. The RT-FluFF assay enables real-time, quantitative assessment of clot lysis under controlled shear flow, directly addressing the limitations of static assays. This platform supports more informed candidate triage and de-risking at the preclinical stage, enhancing portfolio decision-making.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of thrombolytic mechanisms under physiologically relevant flow conditions.
- Supports functional validation of drug targets by mimicking arterial, venous, and pulmonary environments.
- Improves predictive confidence for candidate selection by aligning in-vitro outputs with in-vivo relevance.
Screening & Assay Development
- Facilitates preparation of standardized, flow-formed clots for reproducible screening workflows.
- Delivers quantitative, real-time lysis measurements for robust compound evaluation.
- Enables assay scalability and platform reuse across diverse thrombolytic agents and flow regimes.
Translational & Preclinical Research
- Aligns in-vitro assay conditions with disease-relevant hemodynamics to improve translational continuity.
- Supports risk-adjusted advancement decisions by providing physiologically meaningful efficacy data.
- Reduces reliance on animal models by increasing the fidelity of preclinical in-vitro testing.
Pipeline & Workflow Integration
The RT-FluFF assay bridges early discovery and preclinical evaluation by providing a high-fidelity, quantitative platform for thrombolytic candidate assessment under controlled flow conditions.
- Discovery Biology: Enables hypothesis testing and mechanistic de-risking by simulating in-vivo clot formation and lysis dynamics.
- Screening: Provides reproducible, quantitative readouts for compound comparison and assay standardization.
- Analytics: Supports continuous and endpoint measurements, facilitating robust statistical analysis of lysis kinetics.
- Translational Research: Enhances biomarker alignment and preclinical continuity by modeling physiologically relevant shear and flow.
- Enterprise Reuse: Offers a flexible, adaptable platform for repeated use across multiple drug discovery programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in thrombolytic screening.
- Operational Value: Delivers standardized, reproducible, and scalable assay workflows.
- Strategic Value: Enables better go/no-go decisions and capital efficiency by improving early-stage data quality.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of thrombolytic candidates.
Implementation Considerations
- Requires expertise in hemodynamics, clot biology, and quantitative assay design.
- Needs instrumentation for controlled flow, temperature regulation, and real-time fluorometric detection.
- Demands cross-team standardization of clot formation and digestion protocols.
- Adaptable to various flow rates and clot types to model different vascular conditions.
- Dependent on access to human whole blood and specialized analytical infrastructure.
